欧洲自然杀伤 (NK) 细胞治疗市场 – 行业趋势和 2030 年预测

欧洲自然杀伤 (NK) 细胞治疗市场分析与洞察

欧洲自然杀伤 (NK) 细胞治疗市场的特点包括对更好治疗方案的需求不断增长，这将影响制造商向市场推出新产品，从而增加其需求，以及增加研发投资，从而促进市场增长。目前，正在进行各种研究，预计这将为制造商创造竞争优势，以开发新的创新型 NK 细胞疗法，这有望为市场增长提供各种其他机会。然而，细胞缺乏特异性和体内存活率差，以及与治疗相关的高成本预计将在预测期内抑制市场增长。

欧洲自然杀伤 (NK) 细胞治疗市场具有支持性，旨在减缓疾病的进展。Data Bridge Market Research 分析称，在 2023 年至 2030 年的预测期内，欧洲自然杀伤 (NK) 细胞治疗市场将以 43.3% 的复合年增长率增长。

欧洲自然杀伤 (NK) 细胞治疗市场报告提供了市场份额、新发展、产品线分析、国内和本地市场参与者的影响的详细信息，分析了新兴收入领域、市场法规变化、产品批准、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情况，请联系我们获取分析师简报，我们的团队将帮助您创建收入影响解决方案以实现您的期望目标。

Market Definition

Natural killer (NK) cells are large granular lymphocytes that have the ability to quickly respond to a pathological challenge. They are important components of the innate immune system and play an important role in generating an immune response against malignancies and infectious diseases caused by viral pathogens. They have been recognized to induce the direct killing of targeted cells involving cancer cells. They have the ability to recognize the multitude of infected cells without being dependent on a single antigen-expressing cell.

NK cells secrete cytokines and chemokines that recruit other immune cells such as T cells and B cells, which enhances the immune response against the tumor cells. As NK cells do not express T cell receptors, they induce a low risk of graft-versus-host disease. Moreover, iPSC cell lines derived NK cell therapy that is CAR-NK therapy overcomes the need for a long and complex manufacturing process that allows patients with aggressive tumors to afford tumor treatment as soon as possible. Along with this iPSC derived NK cells can be infused repeatedly, which enhances the immune response with dose regulation.

Europe Natural Killer (NK) Cell Therapeutics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

DRIVERS

• Increase in Patient Population with Chronic Diseases

Chronic diseases are diseases that generally occur in older adults that can be controlled but not cured such as heart disease, arthritis, diabetes, stroke, or cancer. They are a worldwide healthcare problem concern. The change in lifestyle along with physical inactivity, unhealthy diet, and tobacco use is increasing the burden of chronic diseases all over the world.

An increasing number of patients population with chronic diseases led the scientist and researchers to work on a new innovative therapeutic approach so as to provide patients with the best curative treatment option, which can be achieved by using NK cell therapy that has the potential to generate a strong immune response and has the anti-tumor capability as well.

• Rise in Awareness about Immunotherapies

As cancer is a devastating disease and available treatment options may cause the reoccurrence of tumors, the need for the best therapeutic approach is increasing day by day. Immunotherapies have attracted a lot of attention in recent years for the treatment of various types of malignancies. Among the immunotherapies, CAR–T cell therapies have been studied and were used as well but have several limitations, which led to the development of NK cell therapies. As a drug based on an NK cell therapeutic approach has not been approved yet, it thus needs to raise awareness among the population.

This is why several organizations and market players are launching a campaign to enhance awareness regarding NK cell therapies.

OPPORTUNITY

•  Strategic Initiatives by Market Players

Various strategic initiatives are adopted by market players which involve expansion, acquisition, and collaboration among others. These initiatives help them to increase the company’s product portfolio leading to market expansion and hence enhancing the product demand among customers, which ultimately leads the players to earn maximum revenue.

As the demand for effective and affordable NK cell immunotherapy is increasing worldwide, these strategic initiatives are taken by top market players aimed at enhancing business operations and earning more profitability in the market.

RESTRAINT/CHALLENGE

• Lack of Specificity and Poor In Vivo Survival of the cells

Lack of specificity and poor in-vivo survival of NK cells poses a challenge in front of manufacturers dealing in the market. The lack of specificity of NK cells leads to targeting the wrong cells, which can lead to ineffective treatment. Along with this, the lack of specificity and poor in-vivo survival of NK cells also reduces the therapeutic effect of administered NK cell therapy.

Such problems decrease the credibility of therapy used in clinical trials and pose a challenge in front of manufacturers while getting approval.

Recent Developments

• In January 2022, Takeda acquired Adaptate biotherapeutics to develop novel gamma delta (γδ) T cell engager therapies targeting solid tumors. Through the acquisition, Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programs. Adaptate’s γδ T cell engagers are designed to specifically modulate γδ T cell-mediated immune responses at tumor sites while sparing damage to healthy cells. This acquisition helped the company to focus on R&D.
• In December 2021, Nektar Therapeutics announced phase 1b data for novel T regulatory cell stimulator NKTR-358 (LY3471851) in patients with atopic dermatitis. NKTR-358 is designed to treat autoimmune and inflammatory conditions by correcting the immune system imbalance that results from increased levels of inflammatory T cells and reduced numbers and impaired function of immune regulating Treg cells. This has helped the company to focus on R&D for further phases.

欧洲自然杀伤 (NK) 细胞治疗市场范围

欧洲自然杀伤 (NK) 细胞治疗市场根据治疗、方法、应用、最终用户和分销渠道分为五个显著的细分市场。这些细分市场之间的增长将帮助您分析利基增长领域和进入市场的策略，并确定核心应用领域和目标市场的差异。

疗法

• NK 细胞疗法
• NK 细胞定向抗体

根据治疗方法，市场分为 NK 细胞疗法和 NK 细胞定向抗体。

方法

• 抗体依赖性细胞介导的细胞毒性 (ADCC)
• 双特异性抗体

根据方法，市场细分为抗体依赖性细胞介导的细胞毒性 (ADCC) 和双特异性抗体。

应用

• 癌症
• 免疫增生性疾病
• 急性传染病
•  胃肠道疾病
• 其他的

根据应用，市场分为癌症、免疫增生性疾病、急性传染病、胃肠道疾病等。

最终用户

• 研究与学术机构
• 医院
•  专科诊所

根据最终用户，市场分为医院、专科诊所以及研究和学术机构。

分销渠道

• 医院药房
•  直接招标
•  其他的

根据分销渠道，市场分为医院药房、直接招标和其他。

欧洲自然杀伤 (NK) 细胞治疗市场区域分析/见解

欧洲自然杀伤 (NK) 细胞治疗市场分为五个显著部分：治疗、方法、应用、最终用户和分销渠道。

本市场报告涵盖的国家包括德国、法国、意大利、英国、西班牙、荷兰、俄罗斯、瑞士、土耳其、奥地利、挪威、匈牙利、立陶宛、爱尔兰、波兰、卢森堡和欧洲其他国家。

由于技术先进的治疗方法的大规模生产以及新兴市场和行业扩张的需求不断增长，德国在欧洲地区占据主导地位。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了欧洲品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀缺竞争而面临的挑战，以及销售渠道的影响

竞争格局和欧洲自然杀伤 (NK) 细胞治疗市场份额分析

欧洲自然杀伤 (NK) 细胞疗法市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、欧洲业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

欧洲自然杀伤 (NK) 细胞治疗市场的一些主要参与者包括默克公司、百时美施贵宝公司、Glycostem、赛诺菲、EMERcell、Phio Pharmaceuticals、Affimed GmbH、Multimmune GmbH、武田制药有限公司、再生元制药公司和 Bellicum Pharmaceuticals, Inc.

SKU-56947